PBA
INSM icon

Paradigm Biocapital Advisors’s Insmed INSM Stock Holding History

Paradigm Biocapital Advisors’s Portfolio INSM Stock Details INSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$141M Buy
1,325,977
+71,489
+6% +$8.66M 2.65% 13
2026
Q1 		$205M Buy
+1,254,488
New +$193M 4.19% 7
2025
Q2 		– Sell
-451,359
Closed -$34.4M – 33
2025
Q1 		$34.4M Buy
+451,359
New +$34.5M 1.58% 17
2022
Q1 		– Sell
-394,358
Closed -$10.7M – 29
2021
Q4 		$10.7M Buy
+394,358
New +$11.3M 3.07% 13

Other funds holding INSM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Paradigm Biocapital Advisors's INSM Position: Q2 2026 in Review

Paradigm Biocapital Advisors increased its Insmed (INSM) stake by 5.7% in Q2 2026, buying an estimated $8.66M and bringing the position to 1,325,977 shares worth $141M. The position accounts for 2.65% of the portfolio, ranked #13.

Paradigm Biocapital Advisors first reported a position in INSM in Q4 2021 and has held it in 4 quarters since. The position peaked at $205M in Q1 2026. 665 funds tracked by Wall St. Rank hold INSM as of Q2 2026.

  • Paradigm Biocapital Advisors held 1,325,977 shares of Insmed worth $141M as of Q2 2026.
  • Paradigm Biocapital Advisors bought 71,489 Insmed shares in Q2 2026, an estimated $8.66M.
  • Insmed made up 2.65% of Paradigm Biocapital Advisors's portfolio in Q2 2026, its #13 holding.
  • Paradigm Biocapital Advisors first reported a position in Insmed in Q4 2021 and has held it in 4 quarters since.
  • Paradigm Biocapital Advisors's Insmed position peaked at $205M in Q1 2026.
  • 665 funds tracked by Wall St. Rank held Insmed as of Q2 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.